Leap reports positive sirexatamab CRC data: 32% higher ORR, 3.5mo PFS in high DKK1 patients

CYPHERPUNK TECHNOLOGIES INC.

High DKK1 patients: sirexatamab arm ORR 48% vs 15.8% control; median PFS 9.36 vs 5.88 mo (HR 0.46); OS HR 0.09.
No prior anti-VEGF patients: ORR 55.1% vs 32.6%; median PFS 10.94 vs 8.34 mo (HR 0.59); OS immature.
FY2024 net loss $67.6M ($81.4M in 2023); R&D expenses $57.2M ($73.2M in 2023).
Cash and equivalents $47.2M at Dec 31, 2024; engaged financial advisor for business development.
FL-501 abstract accepted at AACR 2025; preclinical data to be presented April 25-30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.